Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-11,400
Closed -$769K 10798
2025
Q3
$769K Buy
+11,400
New +$757K ﹤0.01% 5769
2024
Q1
Sell
-40,000
Closed -$2.86M 9618
2023
Q4
$2.86M Buy
+40,000
New +$2.79M ﹤0.01% 3427
2022
Q3
Sell
-214,000
Closed -$14.8M 10583
2022
Q2
$14.8M Hold
214,000
0.01% 1530
2022
Q1
$16.4M Buy
+214,000
New +$15.4M 0.01% 1581
2017
Q3
Sell
-40,000
Closed -$1.81M 7841
2017
Q2
$1.81M Buy
+40,000
New +$1.77M ﹤0.01% 3107
2015
Q2
Sell
-52,500
Closed -$1.73M 8643
2015
Q1
$1.73M Buy
52,500
+1,000
+2% +$30.7K ﹤0.01% 3065
2014
Q4
$1.38M Buy
+51,500
New +$1.33M ﹤0.01% 3286

Other funds holding HOLX

UBS Group's HOLX Position: Q1 2026 in Review

UBS Group increased its Hologic (HOLX) stake by 62% in Q1 2026, buying an estimated $147M and bringing the position to 5,089,745 shares worth $385M. The position accounts for 0.06% of the portfolio, ranked #339.

UBS Group first reported a position in HOLX in Q4 2014 and has held it in 46 quarters since. 704 funds tracked by Wall St. Rank hold HOLX as of Q1 2026.

  • UBS Group held 5,089,745 shares of Hologic worth $385M as of Q1 2026.
  • UBS Group bought 1,950,084 Hologic shares in Q1 2026, an estimated $147M.
  • Hologic made up 0.06% of UBS Group's portfolio in Q1 2026, its #339 holding.
  • UBS Group first reported a position in Hologic in Q4 2014 and has held it in 46 quarters since.
  • 704 funds tracked by Wall St. Rank held Hologic as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.